Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Glucarpidase is the recombinant form of the Pseudomonas sp. (strain RS-16) enzyme carboxypeptidase G2 that is produced in Escherichia coli. In patients, glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. Therefore since methotrexate is eliminated enzymatically and not by the kidneys, glucarpidase is indicated in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (>1 micromole per liter). Glucarpidase is marketed under the brand name Voraxaze®. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Green JM: Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/TCRM.S30135. Epub 2012 Nov 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23209370 # Tuffaha HW, Al Omar S: Glucarpidase for the treatment of life-threatening methotrexate overdose. Drugs Today (Barc). 2012 Nov;48(11):705-11. doi: 10.1358/dot.2012.48.11.1871575. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23170306 # FDA label. (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - In healthy patients not taking methotrexate, glucarpidase has an elimination half-life of 5.6 hours. In patients with severe renal impairment (creatinine clearance <30 mL/min), glucarpidase has an longer elimination half-life at 8.2 hours. (en)
|
http://linked.open...ugbank/indication
| - Used in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (> 1 micromole per liter). (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. For methotrexate specifically, it is hydrolyzed to the inactive metabolites glutamate and 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA). (en)
|
http://linked.open...outeOfElimination
| - Route of elmination was not determined. (en)
|
http://linked.open.../drugbank/synonym
| - Carboxypeptidase G2 (en)
- Folate hydrolase G2 (en)
- Glutamate carboxypeptidase (en)
- Pteroylmonoglutamic acid hydrolase G2 (en)
|
http://linked.open...drugbank/toxicity
| - Most common adverse reactions include hypotension, flushing, nausea, vomiting, headache, and paresthesia. (en)
|
http://linked.open...umeOfDistribution
| - Glucarpidase is likely limited to the plasma volume since its volume of distribution is 3.6 L. (en)
|
http://linked.open...k/foodInteraction
| - No food effects were found. (en)
|
http://linked.open...nk/proteinBinding
| - Plasma protein binding was not quantified. (en)
|
foaf:page
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...ugbank/absorption
| - In healthy patients not taking methotrexate, the average maximum concentration for glucarpidase was 3.3 μg/mL. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| - In healthy patients not taking methotrexate, glucarpidase has a clearance of 7.5 mL/min. (en)
|